GlassScriptPhysician profile
Lizette Alvarez
NPI 1750342580
$182,399.73
in general payments reported to CMS, 2019-2025
31 companies · $11K in 2025
The $11K reported for 2025 was more than what 98% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $23K · 2021: $52K · 2022: $11K · 2023: $9,077 · 2024: $19K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,486 · Consulting Fee: $1,440 · Travel and Lodging: $1,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,930.00 |
| Food and Beverage | $10,902.18 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,485.71 |
| Consulting Fee | $1,440.00 |
| Travel and Lodging | $1,193.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $119,547.80 | 2019-2022 | |
| Abbvie INC. | $40,044.11 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Piramal Critical Care | $10,966.73 | 2019-2025 | |
| Merz North America, INC. | $3,547.63 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $1,905.47 | 2019-2025 | Dysport |
| Merz Pharmaceuticals, LLC | $1,484.84 | 2021-2025 | Xeomin |
| Avanir Pharmaceuticals, INC. | $1,133.48 | 2019-2022 | |
| Pfizer INC. | $744.48 | 2019-2025 | |
| Medtronic, INC. | $486.88 | 2021-2024 | Intellis Adaptivestim, Synchromedii |
| Otsuka America Pharmaceutical, INC. | $461.82 | 2023-2024 | Nuedexta |
| Biohaven Pharmaceutical Holding Company LTD. | $395.92 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $366.46 | 2020-2021 | |
| Saol Therapeutics INC. | $267.64 | 2019 | |
| Medtronic USA, INC. | $201.09 | 2019-2020 | |
| Axsome Therapeutics, INC. | $143.99 | 2025 | Symbravo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $133.87 | 2019-2021 | |
| Amgen INC. | $122.80 | 2019-2022 | |
| Lundbeck LLC | $71.53 | 2023-2024 | Vyepti |
| Scilex Pharmaceuticals INC. | $65.81 | 2019 | |
| Microtransponder, INC. | $49.17 | 2024 | |
| Mdd US Operations, LLC | $41.95 | 2019-2020 | |
| Averitas Pharma INC. | $36.34 | 2023 | Qutenza |
| Amneal Pharmaceuticals LLC | $28.93 | 2022 | |
| Neuros Medical, INC. | $26.48 | 2025 | Altius |
| Arbor Pharmaceuticals, INC. | $24.37 | 2021 | |
| Supernus Pharmaceuticals, INC. | $18.64 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.58 | 2021 | |
| Bioventus LLC | $17.48 | 2020 | |
| Grt US Holding, INC. | $16.09 | 2022 | |
| 180 Medical, INC. | $15.19 | 2022 | |
| Flowonix Medical Incorporated | $14.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lizette Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.